<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885181</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-379-1582</org_study_id>
    <secondary_id>2016-001496-75</secondary_id>
    <nct_id>NCT02885181</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects With Active Rheumatoid Arthritis on Background Therapy With Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of GS-9876 versus placebo for
      the treatment of signs and symptoms of rheumatoid arthritis (RA) in participants with active
      RA despite methotrexate (MTX) therapy who had an inadequate response to MTX (either alone or
      in combination with biological disease modifying anti-rheumatic drugs [bDMARDs]).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2016</start_date>
  <completion_date type="Actual">September 20, 2017</completion_date>
  <primary_completion_date type="Actual">August 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Disease Activity Score for 28 Joint Count using C-Reactive Protein (DAS28 [CRP]) at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve American College of Rheumatology (ACR) 20/50/70% Improvement at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>GS-9876 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9876 dose A + filgotinib placebo for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9876 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9876 dose B + filgotinib placebo for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib + GS-9876 placebo for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GS-9876 placebo + filgotinib placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9876</intervention_name>
    <description>Tablets administered orally once daily</description>
    <arm_group_label>GS-9876 Dose A</arm_group_label>
    <arm_group_label>GS-9876 Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>Tablets administered orally once daily</description>
    <arm_group_label>Filgotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9876 placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>Filgotinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib placebo</intervention_name>
    <description>2 tablets administered orally once daily</description>
    <arm_group_label>GS-9876 Dose A</arm_group_label>
    <arm_group_label>GS-9876 Dose B</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Background therapy with methotrexate administered orally or parenterally once weekly</description>
    <arm_group_label>GS-9876 Dose A</arm_group_label>
    <arm_group_label>GS-9876 Dose B</arm_group_label>
    <arm_group_label>Filgotinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Active RA disease as defined by: a tender joint count (TJC) of ≥ 6 (out of 68), a
             swollen joint count (SJC) of ≥ 6 (out of 66) at screening and Day 1

          -  Inadequate response to treatment with oral or parenteral MTX 7.5 to 25 mg/week
             continuously for at least 12 weeks, with at least 6 weeks at a stable dose (defined as
             no change in prescription) prior to the first dose of study drug

          -  Participants must be receiving a folic or folinic acid supplementation at a stable
             dose.

        Key Exclusion Criteria:

          -  Prior treatment with B-cell depleting agents (eg, rituximab), unless more than 6
             months prior to the first dose of study drug and documented return of CD19+ cells at
             screening

          -  Prior treatment with any commercially available or investigational spleen tyrosine
             kinase (SYK) inhibitor

          -  Concurrent treatment with any other conventional synthetic DMARD (csDMARD) other than
             MTX and/or hydroxychloroquine (HCQ) (prior csDMARD treatment allowed if appropriate
             wash out as defined in the protocol)

          -  Concurrent treatment with any biological disease modifying anti-rheumatic drug
             (bDMARD)(prior bDMARD treatment allowed if appropriate wash out as defined in the
             protocol). Prior failure to treatment with bDMARDs is not an exclusion criterion.

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Omega Research Consultants</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Arthritis Research Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates of North Georgia</name>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <zip>30114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Arthritis and Osteoporosis</name>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <zip>42701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Center For Rheumatology</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management - Najam</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research Inc.</name>
      <address>
        <city>Stafford</city>
        <state>Texas</state>
        <zip>77477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Research LLC</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT-Plovdiv AD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umhat Kaspela</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NMTH Tsar Boris III</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A-Shine s.r.o.</name>
      <address>
        <city>Plzen</city>
        <zip>31200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Plus, S.R.O.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Arensia Exploratory Medicine</name>
      <address>
        <city>T'bilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine Phase I Unit, Republican Clinical Hospital</name>
      <address>
        <city>Chisinau</city>
        <zip>MD-2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Badurski i wspolnicy Spolka Jawna</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv City Hospital 8</name>
      <address>
        <city>Kharkiv</city>
        <zip>140176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center_Clinic of International Institute of clinical Studies</name>
      <address>
        <city>Kyiv</city>
        <zip>2068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

